Employees: 1,418
Size DocMorris (DOCM.SW) is a Switzerland Health Care company (Medical Distributors) with a market value of $1.08B, the 117th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 18.00 on 18 Nov 2026.
Performance Over six months the shares gained 168.7%, against -3.7% for the median peer and +9.3% for the Switzerland market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 10.6% over the last twelve months (peer median +5.0%); the operating margin is -7.5% (peer median 2.8%).
Valuation It trades at 1.0× enterprise value to sales against a peer median of 0.7× (10th most expensive of 21).
Capital Return on invested capital runs 19.4 points below its cost of capital (6.7% WACC).
Credit DocMorris has 1 bond outstanding ($240M).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | CHF 1.12B | CHF 1.02B | CHF 969M | CHF 931M |
| Revenue growth | — | +11% | +5% | +4% | — |
| Gross profit | n/a | CHF 106M | CHF 71.1M | CHF 51.1M | CHF 6.85M |
| EBITDA | n/a | -CHF 39.4M | -CHF 45.9M | -CHF 32.4M | -CHF 98.9M |
| Net income | n/a | -CHF 134M | -CHF 97.3M | -CHF 114M | -CHF 170M |
| Free cash flow | n/a | -CHF 90.0M | -CHF 27.8M | -CHF 92.3M | -CHF 110M |
| Capital expenditure | n/a | CHF 27.3M | CHF 28.6M | CHF 27.7M | CHF 46.6M |
| Total debt | n/a | CHF 289M | CHF 312M | CHF 331M | CHF 529M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DOCM.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.8% | -0.4% | 4th highest of 21 |
| 6-month return | +168.7% | -3.7% | highest of 21 |
| Distance from 52-week high | -7.7% | -20.2% | 4th highest of 21 |
| Revenue growth (TTM) | +10.6% | +5.0% | 4th highest of 21 |
| Operating margin | -7.5% | 2.8% | 2nd lowest of 21 |
| EV / Sales | 1.0× | 0.7× | 10th most expensive of 21 |
| ROIC minus cost of capital | -19.4 pp | +0.6 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 0.6× | -6.9% | +1.2% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 1.9× | 17.0% | +12.4% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 0.2× | -14.5% | +7.6% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | 0.5× | n/a | n/a |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 0.1× | -4.6% | +5.1% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | 2.1× | -1.6% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | 0.7× | 13.1% | +7.5% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 0.1× | -10.4% | +3.2% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | 2.5× | 26.0% | +9.6% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | 1.1× | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | 4.3× | n/a | n/a |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 1.8× | 4.7% | +12.7% |
DocMorris has 1 bond outstanding with $240M face value.